Drug Trial Radar · NCT05072938
Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis
Last checked: Nov 20, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Sep 30, 2021
Primary completion
Dec 15, 2022
Study completion Dec 15, 2022
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Oct 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis
Conditions
- Gastritis
Interventions
Mucotra SR Tablet 150mgDrug
Rebamipide/Nizatidine Combination Therapy
Axid Capsule 150mgDrug
Nizatidine Monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effective rate of gastric mucosal erosion on the upper gastrointestinal endoscopyTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Catholic University of Korea c St. Mary's Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.